Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 0.80 |
| ▸ | IGF1R | P08069 | 1/20 | 0.80 |
| ▸ | GSK3B | P49841 | 10/20 | 0.74 |
| ▸ | GSK3A | P49840 | 8/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509894 | 1.00 | CDK2 (1.00) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL12505114 | 1.00 | CDK2 (1.00) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL626664 | 1.00 | CDK2 (1.00) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL18687996 | 0.89 | CDK2 (0.80) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL622717 | 0.88 | INSR (0.81) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL622719 | 0.88 | INSR (0.81) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL622718 | 0.88 | INSR (0.81) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL623633 | 0.81 | PIK3CG (0.78) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL623632 | 0.81 | PIK3CG (0.78) | CDK2INSRIGF1RGSK3BGSK3A | |
| SCHEMBL623771 | 0.81 | GSK3B (1.00) | CDK2INSRIGF1RGSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | claimed |
| EP-4215614-A1 | COMBINATION THERAPY FOR DYSTROPHIN-RELATED DISEASES | Dynacure (FR) | 2023-07-26 | — | — | EP | disclosed |
| US-11352624-B2 | Reducing nonsense-mediated MRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200283762-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3690048-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10647983-B2 | Reducing nonsense-mediated mRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2020-05-12 | — | — | US | disclosed |
| US-20170159049-A9 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2017-06-08 | — | — | US | disclosed |
| EP-3094630-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | The Regents of The University of California (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-3041958-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194630-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2016-07-07 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| WO-2015109248-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015035091-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | CDK2 960/4885INSR 4125/4885IGF1R 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.